BIOCHEMICAL SOCIETY TRANSACTIONS dehydrogenases. NAD+ and NADP+ are reducible at the dropping mercury electrode, and the cathodic waves may be measured in the region -1.1 V to -1.3 V. The reduced nucleotides NADH and NADPH are not electroactive at these potentials and thus do not interfere with themeasurements. Under somecircumstances, this polarographic assay for a dehydrogenase may offer advantages over the conventional spectrophotometric method. Such situations include the presence of turbid suspensions, e.g. in the examination of enzyme activities in cells made permeable (Weitzman, 1973), and the presence of NADH oxidase activity. The latter interferes with the normal assay for dehydrogenases, but, under the anaerobic conditions used in polarographic measurements, is inoperative.
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The enzymes measurable by the polarographic procedure may also, of course, serve as coupling enzymes and thereby extend the method to other reactions and the general approach to polarographic assays outlined here should prove applicable to many other enzymes. The ability of polarographs to measure very small currents renders these assay methods comparable in sensitivity with other available (generally spectrophotometric) procedures.
In conclusion, a number of enzyme activities may be determined polarographically. The method is continuous and sensitive, may be performed under a wide range of experimental conditions and is unaffected by solution turbidity. In particular cases, additional advantages may be presented. 
has been studied in rat, rabbit, dog and man. Radioautographic examination of the normal and the pregnant rat given [14C]labetalol orally (50-200mg/kg) or intravenously (25mg/kg) showed that the radioactivity was quickly taken up into the tissues and rapidly cleared from the body via both the kidney and bile. Radiochemical analysis of the plasma and tissues after oral doses to rat, rabbit (50mg of rH]-or [14C]-labetalol/kg) and dog (20mg of ["C]-or [3H]-labetalol/kg) showed that the drug was well absorbed. During absorption, labetalol is extensively metabolized. The difference between the plasma radioactivity and labetalol concentration ( Table 1) has been shown by chromatography of plasma extracts to be due mainly to circulating glucuronide conjugates of labetalol. The highest concentrations of radioactivity were found in the liver, kidneys and bile. The rat excreted 37 %, the rabbit 61 % and the dog 66 % of the dose in the 0-96 h urine. The remainder of the dose of radioactivity was excreted in the faeces. T.1.c. of the urine from rat, rabbit and dog ( Fig. la) showed that the rat excreted 11 % of the dose as labetalol, 5 % of the dose as metabolite (I), 30 % of the dose as metabolite 01) and 1.5 % The solvent system was ethyl acetate/propan-2-ol/water/aq. NH3 (sp.gr. 0.880) (25: 15 : 8 : 2, by vol.), and the plate used was Merck Kieselgel 60 FZs4.
of the dose as metabolite (V). The rabbit excreted 2% of the dose as labetalol, 9 % as metabolite (I) and 55 %as metabolite 01). The dog excreted 19 % of the dose as labetalol, 41 % as metabolite (II)/(III), 3 % as metabolite (IV) and 4% as metabolite (V).
Metabolite (II)/(III) from the dog urine, when incubated with 8-glucuronidase, was only partially hydrolysed to labetalol (Fig. lb) . The addition of arylsulphatase did not result in any further hydrolysis of the metabolite. The metabolite patterns in the urine 563rd MEETING, LONDON were identical irrespective of whether ["C]-or [3H]-labetalol had been administered to the animals; therefore labetalol is not metabolized by N-dealkylation. The urine samples were concentrated on Amberlite XAD-2 resin, and the metabolites were purified by t.1.c. and paper chromatography. Enzymic hydrolysis, chemical analysis, t.l.c., paper chromatography and high-voltage profile electrophoresis (Conway et al., 1973) showed that the rat and rabbit metabolite (11) was the 0-phenyl glucuronide of labetalol, and rat and rabbit metabolite (I) the glucuronide of metabolite (V).
Paper chromatography with solvent butanol/acetic acid/water ( 4 : 1 : 1.6, by vol.) showed that the major dog metaboliteconsisted of two metabolites, with Rp0.54 (16Xof the dose) and RF 0.67 (25 %of the dose). After purification by t.1.c. and paper chromatography the metabolite with RF 0.54 was shown to be the 0-phenyl glucuronide. The other metabolite was a glucuronide that was slowly hydrolysed to labetalol by /?-glucuronidase but not attacked by arylsulphatase. It has been tentatively identified as a glucuronide formed by conjugation of the glucuronyl group with the secondary alcohol group of labetalol.
Mobility-pH profile high-voltage electrophoresis indicated that metabolite (V) contained two phenolic groups. When the metabolite was examined by mass spectrometry the fragmentation pattern obtained confirmed the presence of an extra phenolic oxygen and suggested that the compound was 5-{l-hydroxy-2-[(3-hydroxyphenyl-l-methylpropyl)amino]ethyl}salicylamide. This compound was synthesized and shown to be identical with metabolite (V).
Two male subjects who took 200mg of [3H]labetalol orally (about 3mg/kg) excreted 59 and 61 % of the dose of radioactivity in the urine during 48 h; only in one subject was unchanged drug found (4 % of the dose). Because of the high rate of first-pass metabolism of labetalol by man (Table 1) the clinical dose used for the treatment of hypertension is 600mg or more per day. The major human radioactivemetabolite had RF0.20 on t.1.c. (Fig. la) , but it was only partially hydrolysed to labetalol by glucuronidase. Paper chromatography with butanol/ acetic acid/water (4: 1 : I .6, by vol.) showed that it consisted of two metabolites with RF 0.58 (1 5 % of the dose) and RF 0.7 (45 % of the dose), These were isolated, and the former was shown to be the 0-phenyl glucuronide oflabetalol(I1). The second metabolite was resistant to hydrolysis by glucuronidase and sulphatase, but was hydrolysed by HCI to give labetalol and 2-hydroxy-5-~l-hydroxy-2-[(l-methyl-3-phenylpropyl)-amino]ethyl}benzoic acid. The latter is formed through the hydrolysis of the amide group of labetalol to the carboxylic acid. The major metabolite in man is therefore a conjugate of labetalol, and further work is required to characterize the conjugating group.
Hydroxylabetalol was less active as an a-and 8-receptor antagonist than labetalol, and the conjugates of labetalol were pharmacologically inactive. The rate of protein synthesis in the neurons of the visual cortex of dark-reared rats is decreased compared with that in their normallyreared littermates. When rats reared for 50 days in the dark are exposed to light, there is an increased protein-synthetic rate in the visual cortex, lateral geniculate and retina. At 1 h after onset of illumination and injection of [3H]lysine, most of the increased protein radioactivity is bound to the ribosomes or in a small number of soluble fractions [for a review, see Rose (1976)l. Becaw
